SANUWAVE's CMS Reimbursement Battleground: A Guidance Withdrawal and a 'Used System' Flood

Wound-care device maker faces an existential reimbursement cut, a cannibalized capital market, and a strategic pivot to hospital outpatient.

SNWV · Earnings Call · 2026-08-07

The Second Quarter: Applicators Up, Systems Down

SANUWAVE Health (SNWV) reported Q2 2026 results that captured the paradox of a company with a durable recurring-core growth engine but a capital equipment business in freefall. While applicator revenue grew 13% year-over-year and unit volume jumped 27%, total revenue fell 3% to $9.7 million, dragged by a 34% decline in system sales. The company attributed the divergence to a system sales miss versus expectations, and specifically to a shift toward wholesale/reseller pricing. As Chairman and CEO Morgan Frank noted, “The divergence on price is predominantly from a shift to a reseller model and the company selling applicators at wholesale prices.” — Morgan Frank, Chairman and CEO · 2026-08-07 The reseller shift was itself a response to a market convulsing under the weight of CMS reimbursement cuts for skin substitutes, which have driven many wound-care providers into bankruptcy. This created an unprecedented secondary market for used UltraMIST devices, directly cannibalizing new system sales. Frank sized the impact: “Our best guess is that used systems accounted for 40 to 60 system sales in the quarter.” — Morgan Frank, Chairman and CEO · 2026-08-07 He acknowledged the difficulty in precise measurement, but the overhang is clear: the installed base is growing only modestly (1,411 active systems, up from 1,382), and the market for new capital equipment is severely pressured.

The CMS Loom: Proposed Rule and Comment Period

The more existential threat came in July, when CMS proposed a drastic cut to reimbursement for the 97610 code — the treatment code used for UltraMIST. The company’s read is that reimbursement would fall from $397 to approximately $316 in 2027, with further reductions in 2028. Management expressed firm disagreement with the assumptions behind the proposal, stating “We disagree with a number of the assumptions CMS is using to arrive at these figures.” — Morgan Frank, Chairman and CEO · 2026-08-07 They intend to fight the rule during the comment period that runs through September 14, and the final rule is expected in early November. The uncertainty was enough to force the withdrawal of full-year revenue guidance. Frank’s language was unequivocal:

Owing to the market conditions, including the Medicare reimbursement developments discussed previously, SANUWAVE is withdrawing its previously issued fiscal year 2026 revenue guidance, which should no longer be relied upon.
Morgan Frank, Chairman and CEO · 2026-08-07

This guidance withdrawal is a stark departure from the tone of prior calls, where management touted a strong pipeline and seasonal upside. Back in May, Frank had emphasized “this is traditionally a fairly seasonal business” — Morgan Frank, Chairman and CEO · 2026-05-13 and pointed to a favorable back-half trend — a confidence that now feels distant.

The Used System Market and Customer Distress

The used-system cannibalization is emblematic of a broader industry shakeout. Providers who built practices around skin substitute reimbursement are closing doors or shedding assets. The company has spent quarters describing a skin sub reimbursement crisis, but this quarter brought the consequence directly into its own sales numbers. Frank noted that “the used systems coming up for sale stand testament to this,” and the company now sees a secondary channel that it cannot fully monitor. This creates a pragmatic shift: the recurring applicator business remains the anchor, but the capital equipment engine is impaired. Management’s response has been to double down on longer-term, higher-retention channels — hospital outpatient, HOPD, and post-acute settings — which they believe are more resilient and less prone to reimbursement-driven churn. This strategic pivot is visible in the company’s Hospital Outpatient focus, and in the proposed 14% reimbursement increase for UltraMIST in the 2027 HOPD proposed rule, a rare piece of good news. The financial pressure is visible in the fundamentals. Total revenue peaked at $11M in 2025Q3 and has since slipped to $10M. Gross margin has held near 77%, but the mix shift toward consumables and wholesale pricing is pressuring the trajectory. Meanwhile, operating income swung to a $1M loss in the latest quarter, and the company’s stock has fallen 72.6% in the last 90 days — a reflection of the market’s de-rating of the business given reimbursement risk.

Strategic Response and Longer-Term Push

Despite the near-term pain, management is positioning the company for a rebound. The comment period provides a platform to advocate for accurate data, and the company is rallying users and academics to submit feedback. Frank was optimistic: “We believe that there is a strong case to be made. I mean, we wouldn’t be the first company to get such a proposed rule overturned or reassessed, and we’re going to try very, very hard to be the next one.” The longer-term push into underserved markets — rural, long-term care, and hospital inpatient — is intended to create a more sticky customer base. This mirrors the earlier themes of expanding white space, but the near-term catalyst is now entirely tied to the CMS outcome. If the final rule is softened, the stock could re-rate; if not, the company faces a much harder path. In summary, SANUWAVE is at a crossroads. The recurring applicator business is healthy, but the capital equipment model is being crushed by both reimbursement cuts and a flooded used-equipment market. The company has withdrawn guidance, is fighting the CMS proposal, and is betting on a strategic shift toward hospital outpatient. The next few months will be decisive.